Scholarlink

Background <p>Pre-clinical data demonstrated anti-tumour effect in Ewing sarcoma (ES) for zoledronic acid. This provided the rationale for the second randomisation (R2) in the EURO EWING 2012 (EE2012) trial, whether the addition of zoledronic acid to consolidation chemotherapy improved clinical outcomes.</p> Methods <p>EE2012 was a European academic, open-label, randomised controlled phase III clinical trial. Patients with ES or Ewing-like sarcomas were included (R1). Patients meeting the R2 eligibility criteria (age 5–49 years) were randomised (1:1) to receive either nine cycles of zoledronic acid or no zoledronic acid with the R1 allocated consolidation chemotherapy. Primary and secondary outcome measures were event-free and overall survival, respectively.</p> Findings <p>Between 12-Aug-2014 and 20-Sep-2019, of the 640 R1 patients, 272 patients (136 in each group) were enrolled to R2. Median follow-up was 5.5 years. Three-year EFS was 59% in the zoledronic acid group and 57% in the no zoledronic acid group (adjusted hazard ratio = 0·92 (95% CI: 0·64, 1.31), <i>p</i> = 0.632). Three-year OS was 75% for both groups (adjusted hazard ratio = 0.84 (95% CI: 0.56, 1.25), <i>p</i> = 0.386).</p> Conclusion <p>Adding zoledronic acid did not improve clinical outcomes in ES.</p> Trial registration <p>The trial was prospectively registered with EudraCT 2012-002107-17 and ISRCTN 54540667.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma—EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial

  • 期刊论文

  • 发表日期：

    2026年3月15日

查看全文
  • Brennan Bernadette,
  • Laura Kirton,
  • Perrine Marec-Bérard,
  • Nathalie Gaspar,
  • Valerie Laurence,
  • Javier Martín-Broto,
  • Hans Gelderblom,
  • Cormac Owens,
  • Jennifer Anderton,
  • Sandra J. Strauss,
  • Jane Wingrove,
  • Veronica Moroz,
  • Jeremy Whelan,
  • Lisa L. Hjalgrim,
  • Keith Wheatley,
  • Piers Gaunt

摘要

Background

Pre-clinical data demonstrated anti-tumour effect in Ewing sarcoma (ES) for zoledronic acid. This provided the rationale for the second randomisation (R2) in the EURO EWING 2012 (EE2012) trial, whether the addition of zoledronic acid to consolidation chemotherapy improved clinical outcomes.

Methods

EE2012 was a European academic, open-label, randomised controlled phase III clinical trial. Patients with ES or Ewing-like sarcomas were included (R1). Patients meeting the R2 eligibility criteria (age 5–49 years) were randomised (1:1) to receive either nine cycles of zoledronic acid or no zoledronic acid with the R1 allocated consolidation chemotherapy. Primary and secondary outcome measures were event-free and overall survival, respectively.

Findings

Between 12-Aug-2014 and 20-Sep-2019, of the 640 R1 patients, 272 patients (136 in each group) were enrolled to R2. Median follow-up was 5.5 years. Three-year EFS was 59% in the zoledronic acid group and 57% in the no zoledronic acid group (adjusted hazard ratio = 0·92 (95% CI: 0·64, 1.31), p = 0.632). Three-year OS was 75% for both groups (adjusted hazard ratio = 0.84 (95% CI: 0.56, 1.25), p = 0.386).

Conclusion

Adding zoledronic acid did not improve clinical outcomes in ES.

Trial registration

The trial was prospectively registered with EudraCT 2012-002107-17 and ISRCTN 54540667.